6493 RESULTS
Sort By:
U.S. guidelines for assessing Alzheimer's disease (AD) neuropathology are getting a much-needed facelift. The existing ones, in place since 1997, had fallen out of step with the current understanding of AD as a disease with a long preclinical stage.
Move over, genome, transcriptome, proteome. The latest ome aims to map every metabolite linked to human health and disease. Metabolomics, although still a nascent field, offers hope for biomarkers and treatments in neurodegenerative disease. The field
CRISPR Gene Editing—Poised to Revolutionize Neuroscience? Neuroscientists Probe CRISPR Transgenics and Treatment Paradigms
Alzforum readers might be forgiven for thinking all microglia do is act prominently, if mysteriously, in Alzheimer's pathogenesis. Not so. A recent flurry of papers shows that microglia can match themselves specifically to GABA synapses. They can rev
Last year's ice bucket challenge for amyotrophic lateral sclerosis netted $220 million in donations for ALS charities, and the 2015 challenge is off to a strong start with $100,000 from Major League Baseball. Alzforum looks at how all that money is b
The rarest kind of Alzheimer's disease, the form that is inherited from parent to child with a cruel 50 percent likelihood, has long been marked by its untapped opportunities. Affected families have made possible both the discovery of the first three
As populations age worldwide and the number of people with dementia is set to soar over the next few decades, a crisis in eldercare looms. At the same time, the use of personal technology—smartphones, tablets, wearable monitors—is exploding. Can technolog
Are you curious about trying iPS cell lines to model the disease you care about? Intrigued but nebulous on where the field is at? Ready to grow an iPS line but not sure where to turn? Read Madolyn Rogers's four-part series to learn all about who does
Have neuroscientists entered the era of the programmable brain? Thanks to optogenetics and pharmacogenetics, which let scientists switch neuronal activity on or off with light or designer drugs, scientists can now control specific subtypes of neurons in r
With the nation at war for eight continuous years, and awareness of the dangers of sports concussions on the rise, a new priority—and opportunity—are taking shape for neurodegenerative disease researchers. In a time of austere budgets, the Department of D
Alzforum readers who follow the science of preclinical Alzheimer's and prevention may have heard about three independent but complementary programs that together are laying the groundwork for secondary prevention trials across the spectrum of rare to
Did you know that if you had a spinal tap for a cerebrospinal fluid-based Alzheimer's diagnosis in Boston, Stockholm, London, or San Diego, the readout would likely be different in each place? And different again this year and next? That's a pro
Modern Microscopy Skims Surface of Living Minds and Spines Modern Microscopy Plumbs the Depths of Brain Tissue
Online training for use of Amyvid, the first FDA-approved Aβ imaging ligand, is now up and running,even as a task force convened by the Society of Nuclear Medicine and the Alzheimer's Association scrambles to formulate some expert guidelines on how a
Two weeks after the FDA gave the nod to aducanumab, the aftershocks continue to reverberate. Critics are lambasting the agency, three members of its advisory committee resigned, and the drug’s cost has ignited calls for pricing reform. Meanwhile, Alzheime
No filters selected
